



2024 Annual Report



2	President's Message
3	AMP Strategic Plan
4	2024 Board of Directors
5	Organizational Relationships
7	Advancing Molecular Medicine
8	Innovation & Improved Patient Care
9	Membership
10	Annual Meeting and Conferences
11	Education & Professional Development
12	Finances

CONTENTS

Dear Colleagues, Patients and Friends,

2024 has been a year of momentum and measurable progress for the Association for Molecular Pathology. I am proud of the many ways AMP has continued to lead the field.

Among our most consequential efforts was our decision to challenge the U.S. Food and Drug Administration's final rule, which would regulate laboratory-developed testing procedures as medical devices. AMP filed a federal lawsuit in August, arguing that this overreach threatens patient access to accurate and timely diagnostic testing.

Our commitment to preserving innovation and protecting the integrity of laboratory-developed procedures is unwavering, and we will continue to take bold action to defend the future of molecular medicine and our patients.

Also this year, we expanded our global reach by welcoming molecular professionals from around the world to our annual meeting in Vancouver, Canada. The event served as a catalyst for collaboration, with participants exchanging insights on emerging technologies, clinical challenges and regulatory developments from their respective regions. The global engagement underscored AMP's growing influence and the universal importance of advancing molecular diagnostics worldwide.

We remain committed to providing the highest quality educational programming and clinical practice guidelines to support our members at every stage of their careers. By equipping the molecular pathology workforce with timely, evidence-based resources, AMP continued to elevate clinical practice and improve outcomes for patients worldwide.

Many thanks to the dedicated members and staffers who make this important work possible. Your expertise, energy and collaboration are what make AMP a community unlike any other. You are the reason that AMP continues to serve as a trusted leader in molecular diagnostics.

Sincerely,

Maria E. Arcila, M.D.

Memorial Sloan Kettering Cancer Center

President, Association for Molecular Pathology



PRESIDENT'S MESSAGE



Strategic Plan

AMP's strategic plan is dynamic. Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic goals and objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP's mission, vision and core principles.

Mission

The Association for Molecular Pathology is a not-for-profit scientific society that advances the clinical practice, science, and excellence of molecular and genomic laboratory medicine through education, innovation, and advocacy to enable highest quality health care.

Vision

The Association for Molecular Pathology provides global expertise in molecular testing that drives patient care.

Core Principles

- Quality health care through excellence in clinical molecular testing
- Fostering a diverse and inclusive global community of molecular pathology professionals
- Collaboration to advance molecular pathology and improve equity in the delivery of molecular laboratory testing
- Advocacy that advances the field and practice of molecular pathology, protects patients and improves the adoption of innovative technologies and tests
- Innovation to transform patient care



President
 President-Elect
 Past President
 Secretary Treasurer
 Clinical Practice Committee Chair
 Early Career Member
 Early Career Member
 Economic Affairs Committee Chair
 International Affairs Committee Chair
 Membership Affairs Committee Chair
 Professional Relations Committee Chair
 Program Committee Chair
 Publications Committee Chair
 Training & Education Committee Chair
 Genetics Subdivision Chair
 Hematopathology Subdivision Chair
 Infectious Diseases Subdivision Chair
 Informatics Subdivision Chair
 Solid Tumors Subdivision Chair
 Chief Executive Officer

Maria E. Arcila, M.D.
Jane S. Gibson, Ph.D.
Laura J. Tafe, M.D.
Yasmine M.N. Akkari, Ph.D.
Susan J. Hsiao, M.D., Ph.D.
Adam Fisch, M.D., Ph.D.
Panieh Terraf, Ph.D.
Jay Patel, M.D.
Rami Mahfouz, M.D.
Yaolin Zhou, M.D.
Eric Konnick, M.D.
Jonathan A. Nowak, M.D., Ph.D.
Patricia Tsang, M.D.
Marjorie Parker David, M.D.
Matthew Lebo, Ph.D.
Rena R. Xian, M.D.
Kirsten St. George, Ph.D.
Annette Leon, Ph.D.
Anthony N. Snow, M.D.
Laurie Menser, CAE

2024 BOARD OF DIRECTORS

In support of our mission and core principle of collaboration, AMP maintains membership in and formal representation with a range of professional societies, coalitions and advocacy groups working to advance molecular pathology, improve patient access to testing and promote equity in care. The list below highlights key organizations but is not exhaustive.

AMP maintains membership in the following organizations:


- American College of Surgeons American Joint Committee on Cancer (AJCC)
- Association for Pathology Informatics (API)
- BLOODPAC
- Cancer Leadership Council (CLC)
- Federation of American Societies for Experimental Biology (FASEB)
- Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
- Intersociety Council for Pathology Information (ICPI) — Associate Member
- Intersociety Pathology Council (IPC)
- Personalized Medicine Coalition (PMC)
- World Health Organization International Agency for Research on Cancer (IARC)

ORGANIZATIONAL RELATIONSHIPS




AMP has formal representation in many groups, including, but not limited to, the following:

- American Board of Pathology (ABP) — Cooperating Society
- College of American Pathology (CAP)
 - Pathology Coding Caucus (PCC) — Representative
 - Molecular Oncology and Genomic Medicine Resource Committees — Representatives
 - Pathology and Laboratory Quality Center for Evidence-Based Guidelines Expert Panels — Representatives
- Centers for Disease Control and Prevention
 - Surge Capacity Memorandum of Understanding Partners
 - Forum on Adoption of Standards for Laboratory Data Exchange and Interoperability
- ClinGen Somatic Cancer Clinical Domain Workgroup — Representative
- Food and Drug Administration
 - Network of Experts
 - Systemic Harmonization and Interoperability Enhancement for Laboratory Data (SHIELD) — Representative
- Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Steering Committees — Representatives
- Intersociety Council for Pathology Information (ICPI) — Associate Member
- National Academies Roundtable on Genomics and Precision Health — Sponsor
- National Institute of Standards and Technology Genome in A Bottle Consortium — Steering Committee
- Test Renaming for Understanding and Utilization for Laboratory Test Names (TRUU-Lab) — Representatives



ORGANIZATIONAL RELATIONSHIPS CONTINUED



AMP pursued a wide range of economic and policy initiatives in 2024, including:

- Filed a lawsuit against the U.S. Food and Drug Administration over its final rule for laboratory-developed testing procedures
- Participated in 49 meetings on Capitol Hill about gene patenting, oversight of laboratory-developed testing procedures, our CLIA modernization proposal and more
- Published a report on the impacts of the European Union's new standards for manufacturers of medical device and in vitro diagnostics
- Participated in the Clinical Laboratory Fee Schedule annual payment determination process
- Engaged the U.S. Centers for Medicare & Medicaid Services on coverage and pricing topics relevant to AMP membership
- Issued 21 position statements and letters
- Developed new patient-facing resources on screening versus diagnostic testing in breast cancer and hepatitis C

For more information about AMP's advocacy efforts, please visit our [Position Statements & Letters webpage](#).

ADVANCING MOLECULAR MEDICINE



AMP supports the creation of definitive evidence-based clinical practice guidelines; however, rapidly emerging scientific and clinical evidence requires several formats of AMP guidelines. Regardless, the recommendations proposed by AMP guidelines reflect a systematic search for and review of published clinical and scientific evidence and the expertise of subject matter experts. All AMP-led guidelines undergo independent peer review, are published in *The Journal of Molecular Diagnostics* and are available for free download (complete list available at amp.org/clinical-practice/practice-guidelines).

The following were published in 2024:

DPYD Genotyping Recommendations

A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium (DOI: [10.1016/j.jmoldx.2024.05.015](https://doi.org/10.1016/j.jmoldx.2024.05.015))

Recommendations for Tumor Mutational Burden Assay Validation and Reporting

A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer (DOI: [10.1016/j.jmoldx.2024.05.002](https://doi.org/10.1016/j.jmoldx.2024.05.002))

Slice Testing — Considerations from Ordering to Reporting


A Joint Report of the Association for Molecular Pathology, College of American Pathologists, and National Society of Genetic Counselors (DOI: [10.1016/j.jmoldx.2023.11.008](https://doi.org/10.1016/j.jmoldx.2023.11.008))

Collaboration as both a core value and daily activity:

- Our multidisciplinary volunteer working groups address molecular medicine practice challenges in oncology, genomics, infectious disease and informatics.
- Most published AMP-led guidelines were collaboratively developed: 37 representatives from 13 professional organizations have participated, with 15 guidelines also receiving organizational prepublication endorsements.
- 40+ representatives from 16 different professional organizations are currently serving on one or more of AMP's 15+ active clinical practice working groups.
- 50+ professional organizations have invited AMP to formally collaborate on clinical practice related topics.
- 100+ AMP member external representatives have provided subject matter expertise to 75+ projects, committees or workgroups.
- The Clinical Practice Committee, scientific subdivisions and Publications Committee work collaboratively with AMP education and advocacy groups to address important topics comprehensively.

Interested in collaborating with AMP? Contact our clinical affairs team at AMPClinicalPractice@amp.org.

INNOVATION & IMPROVED PATIENT CARE



Our community consists of healthcare professionals who are committed to helping people. Our field is best served by amplifying diverse voices in our community and including representation from across the spectrum of our community in everything we do. We work together to address inequities for patients.

Total AMP membership grew for the 18th year in a row in 2024, surpassing **3,000 members** for the first time.

New members welcomed in 2024: **766** **3,161** **72**
MEMBERS COUNTRIES

Primary degrees held by AMP members:

928 **965** **460** **805**
M.D. PH.D. M.D., PH.D. BACHELOR’S, MASTER’S AND OTHER DEGREES

AMP membership by type:

1,869 **285** **981** **26**
REGULAR MEMBERS TECHNOLOGIST MEMBERS ASSOCIATE MEMBERS EMERITUS MEMBERS
(students, residents and fellows) (retired)

International Affiliates:

- The Hong Kong Society for Molecular Diagnostic Sciences
- The Korean Society for Laboratory Medicine
- The Molecular Pathology Association of India
- The German Society of Pathology
- Brazilian Society of Clinical Pathology and Laboratory Medicine
- The Italian Society of Pathology and Translational Medicine
- American University of Beirut Medical Center
- Middle East Molecular Biology Sources
- Asociacion Iberoamericana de Patologia Molecular

MEMBERSHIP



The AMP 2024 Annual Meeting & Expo was held in Vancouver, British Columbia, Canada, in November.

We welcomed more than 1,500 attendees and more than 150 exhibiting companies for a dynamic week of scientific dialogue, learning and community-building.

More than 500 poster presentations enlivened the expo floor, highlighting innovative work from laboratory professionals around the world. Abstracts from those presentations are freely available in AMP's official journal, *The Journal of Molecular Diagnostics* (DOI: [10.1016/S1525-1578\(24\)00232-0](https://doi.org/10.1016/S1525-1578(24)00232-0)).



AMP hosted the 2024 Economics Summit in Washington, D.C., in August.

The fourth event of its kind, it was designed to identify barriers to appropriate reimbursement for molecular pathology procedures; examine the impact of these barriers on various stakeholders and patient access to care; and propose potential solutions and/or novel approaches to overcoming barriers to implement shared policy goals from participating stakeholders in oncology, infectious diseases and inherited conditions.

The event attracted 57 attendees. The meeting report is available at amp.org/advocacy.



AMP Europe 2024 was held in Madrid, Spain, in June.

Over three days, the meeting featured dozens of speakers at invigorating general sessions, industry spotlights and breakout events. AMP Europe also offered networking activities and poster presentations, the abstracts for which are freely available in *JMD* (DOI: [10.1016/S1525-1578\(24\)00122-3](https://doi.org/10.1016/S1525-1578(24)00122-3)).

We sincerely thank our community, exhibitors, partners and corporate sponsors for their ongoing support of AMP scientific and advocacy events.

ANNUAL MEETING & CONFERENCES



AMP's education portfolio continued to grow in 2024 through expanded offerings of live webinars, on-demand recorded content and self-paced courses and certificate programs on AMPED™.

We published more than 23 hours of new recorded content this year, including 17 webinars and two courses, and more than 50 hours of material from the 2024 annual meeting.


Other points of pride:

- More than **37,000 users** visited AMPED™, resulting in more than **292,000 pageviews**.
- >300 hours of content available on AMPED™
- AMP partnered with **four educational providers** to create new resources.
- Over 90% of 2024 MGP diplomates used AMP's Fellowship In-Service Exam and over 95% of 2024 MGP diplomates used other AMP education resources on AMPED™
- **GetAMPed!** at the 2024 annual meeting attracted 104 attendees.
- Provided support to the MGP Program Directors Council to launch the inaugural **NRMP MGP Fellowship Match** for MGP programs nationwide

We greatly appreciate the volunteers, partners and corporate sponsors who enable AMP's essential education initiatives.

EDUCATION & PROFESSIONAL DEVELOPMENT





**STRATEGIC INITIATIVE
REVENUE OVER EXPENSES**

	2024	2023	2022
Advocacy	\$ (1,827,049)	\$ (736,955)	\$ (184,444)
Communications & Outreach	\$ (160,480)	\$ (193,014)	\$ (202,822)
Education	\$ 1,648,578	\$ 1,712,267	\$ 1,793,395
Innovation & Improved Patient Care	\$ (469,428)	\$ (560,820)	\$ (129,286)
Membership & Management Services	\$ (331,883)	\$ (324,519)	\$ (227,834)
EXCESS REVENUE OVER EXPENSES	\$ (1,140,262)	\$ (103,042)	\$ 1,049,009

Please note that in 2024 the AMP Board of Directors approved a budget deficit to pay for AMP’s lawsuit against the U.S. Food and Drug Administration over its final rule on oversight of laboratory-developed testing procedures.



ASSOCIATION
FOR MOLECULAR
PATHOLOGY

**6120 Executive Boulevard
Suite 700
Rockville, Maryland, 20852**

amp.org

